Neena M. Patil Sells 3,700 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jazz Pharmaceuticals Trading Down 2.6 %

Shares of Jazz Pharmaceuticals stock opened at $124.27 on Friday. The firm has a market cap of $7.51 billion, a price-to-earnings ratio of 17.50, a PEG ratio of 1.07 and a beta of 0.57. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business has a 50-day moving average price of $111.61 and a 200-day moving average price of $110.18.

Analysts Set New Price Targets

Several research firms recently weighed in on JAZZ. Wells Fargo & Company cut their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. TD Cowen decreased their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, Royal Bank of Canada raised their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Jazz Pharmaceuticals by 46.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 14,593 shares of the specialty pharmaceutical company’s stock valued at $1,626,000 after buying an additional 4,627 shares during the period. ARGA Investment Management LP raised its stake in Jazz Pharmaceuticals by 83.9% in the third quarter. ARGA Investment Management LP now owns 12,195 shares of the specialty pharmaceutical company’s stock worth $1,359,000 after buying an additional 5,562 shares in the last quarter. Captrust Financial Advisors raised its stake in Jazz Pharmaceuticals by 9.5% in the third quarter. Captrust Financial Advisors now owns 4,965 shares of the specialty pharmaceutical company’s stock worth $553,000 after buying an additional 430 shares in the last quarter. Capstone Investment Advisors LLC bought a new position in Jazz Pharmaceuticals in the third quarter worth approximately $327,000. Finally, Rockefeller Capital Management L.P. raised its stake in Jazz Pharmaceuticals by 1.4% in the third quarter. Rockefeller Capital Management L.P. now owns 246,404 shares of the specialty pharmaceutical company’s stock worth $27,452,000 after buying an additional 3,307 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.